High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis

Alexander Greb, Julia Bohlius*, Sven Trelle, Daniel Schiefer, Carmino A. De Souza, Christian Gisselbrecht, Tanin Lntragumtornchai, Ulrich Kaiser, Hanneke C. Kluin-Nelemans, Maurizio Martelli, Noel Jean Milpied, Gino Santini, Leo F. Verdonck, Umberto Vitolo, Guido Schwarzer, Andreas Engert

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

80 Citations (Scopus)

Abstract

Background: Randomized controlled trials (RCTs) reported conflicting results on the impact of high-dose chemotherapy (HDCT) and autologous stem cell transplantation in the first-tine treatment of patients with aggressive non-Hodgkin lymphoma (NHL). Methods: We performed a systematic meta-analysis to assess the efficacy HDCT compared to conventional chemotherapy in aggressive NHL patients with regard to complete response (CR), overall survival (OS), event-free survival (EFS), toxicity, and impact of the age-adjusted International Prognostic Index (aalPI) risk factors. We searched the Cochrane Library, MEDLINE and other databases (1 / 1990 to 1 /2005). Hazard ratio (HR), relative risks (RR) and 95% confidence intervals (Cis) were calculated using the fixed effect model. Results: Fifteen RCTs including 2728 patients were identified. HDCT improved CR when compared to conventional chemotherapy (RR 1.11, CI 1.04-1.18). Overall, there was no evidence for HDCT to improve OS (HR 1.05, 95% CI 0.92-1.19) or EFS (HR 0.92, 95% CI 0.80-1.05) when compared with conventional chemotherapy. However, subgroup analysis indicated OS differences (p = 0.032) between good (HR 1.46, 95% CI 1.02-2.09) and poor risk (HR 0.95, 95% CI 0.81-1.11) patients. Conflicting results were reported for poor risk patients, where some studies reported improved and others reduced OS and EFS after HDCT. Conclusion: There was no evidence that HDCT improved OS and EFS in good risk NHL patients. The evidence for poor risk patients is inconclusive. HDCT should not be further investigated in good risk patients with aggressive NHL but high quality studies in poor risk patients are warranted. (C) 2007 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)338-346
Number of pages9
JournalCANCER TREATMENT REVIEWS
Volume33
Issue number4
DOIs
Publication statusPublished - Jun-2007

Keywords

  • BONE-MARROW-TRANSPLANTATION
  • INTERNATIONAL PROGNOSTIC INDEX
  • 3-WEEKLY CHOP CHEMOTHERAPY
  • RANDOMIZED-TRIAL
  • MACOP-B
  • CONVENTIONAL CHEMOTHERAPY
  • ITALIAN MULTICENTER
  • MALIGNANT LYMPHOMA
  • INTERMEDIATE-GRADE
  • ELDERLY-PATIENTS

Cite this